## nature research

Corresponding author(s):	Brent S Pedersen
Last updated by author(s):	2021-05-2021

## **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

<u> </u>				
St	· a:	tic	:†1	CC

For	all statistical an	alyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	$\square$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
	A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
$\boxtimes$	The statistical test(s) used AND whether they are one- or two-sided  Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
$\boxtimes$	A description of all covariates tested				
$\boxtimes$	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
$\boxtimes$	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
$\boxtimes$	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
$\boxtimes$	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
$\boxtimes$	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
$\boxtimes$	$\square$ Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Policy information about <u>availability of computer code</u>					
Da	ata collection	No software was used.			
Da	ata analysis	All analyses were performed using slivar with parameters described in the manuscript and listed in the rare-disease section of the slivar wiki.			

## Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

Code to derive the best practices filtering is included in the slivar github repository in the paper/ folder.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RGP Sequence data is available via: https://raregenomes.org/data-sharing.

Ewing Sarcoma data is in dbGap Study Accession: phs001228.v1.p1.

CHD data is in dbGap Study Accession: dbGaP phs000744.

The clinical exome data obtained from ARUP Laboratories for the main exomes for this study was approved for de-identified research use by the Institutional Review Board of the University of Utah. However, ARUP legal counsel has determined that the clinical testing consent form signed by these patients does not allow for the full sharing of raw data to any publicly available database.

 $The genome-in-a-bottle\ data\ is\ available\ from:\ ftp://ftp-trace.ncbi.nlm.nih.gov/giab/ftp/release/AshkenazimTrio/HG002\_NA24385\_son/NISTv4.1/GRCh37/AshkenazimTrio/HG002\_NISTv4.1/GRCh37/AshkenazimTrio/HG002\_son/NISTv4.1/GRCh37/AshkenazimTrio/HG002\_son/NISTv4.1/GRCh37/Ashkenazim$ 

Figures 1, 2, 3, 4, 5 were created from the raw data.					
rieiu-spe	cific reporting				
Please select the or	ne below that is the best fit for y	our research. If you are not sure, read the appropriate sections before making your selection.			
\times Life sciences	Behavioural & soci	al sciences Ecological, evolutionary & environmental sciences			
For a reference copy of t	the document with all sections, see <u>nature</u>	.com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces study desi	gn			
All studies must disclose on these points even when the disclosure is negative.					
Sample size	We used the largest cohorts available to us.				
Data exclusions	We excluded low-quality samples f	rom the RGP data identified as outliers in various Quality Control plots			
Replication	We added replication cohorts for both exome and whole genome.				
Randomization	NA				
Blinding	Blinding was not relevant to this study.				
Reporting for specific materials, systems and methods					
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.					
Materials & exp	perimental systems	Methods			
n/a Involved in th	ne study	n/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic	cell lines	Flow cytometry			
Palaeontology and archaeology		MRI-based neuroimaging			
	Animals and other organisms				
Human research participants					
Clinical data					
Dual use research of concern					